Principal Investigator
Clinical Trial ID
Clinical Trial Summary
The purpose of the study is to assess the use of Multikinase Inhibitors (MKIs) in the
treatment of patients with a progressive differentiated thyroid carcinoma (DTC) refractory to
radioactive iodine (RAI) who do not have any symptoms.
Phase
N/A
Funding Agency/Sponsor
Bayer
Disease
Thyroid and Other Endocrine Cancers
Enrollment Eligibility
Inclusion Criteria:
- Histologically/cytologically documented DTC (papillary, follicular, Hurthle cell, and
poorly differentiated carcinoma)
- DTC refractory to RAI
- Radiological progression and preferably according to RECIST 1.1
- No symptoms due to DTC
- >/=1cm diameter of lesion confirmed by radiological exam
- Life expectancy of at least 6 months
Exclusion Criteria:
- Plan to be treated according to a clinical trial protocol for intervention including a
locoregional therapy or systemic therapy
- Previous treatment with MKIs for advanced disease
- Hospice patients